Effect of silymarin in inflammatory bowel disease

Evaluation of the effect of silymarin in patients with inflammatory bowel disease

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20101107005123N3

Enrollment

Registered

2023-02-18

Start date

2023-04-21

Completion date

Unknown

Last updated

2023-03-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inflammatory Bowel Disease. Noninfective inflammatory bowel disease

Interventions

Intervention 1: Intervention group: Silymarin tablets (Gol Daro Company) with a dose of 5 mg/kg in divided doses three times a day for three months on a daily basis. Intervention 2: Control group: Thr

Eligibility

Sex/Gender

All

Age

5 Years to 18 Years

Inclusion criteria

Inclusion criteria: Inflammatory bowel disease

Exclusion criteria

Exclusion criteria: The patient's unwillingness to visit the gastroenterology clinic regularly for regular examinations and check-ups Presence of any other comorbidities

Design outcomes

Primary

Measure	Time frame
Clinical Symptoms. Timepoint: Before the start of the study, one month and three months after the start of the intervention. Method of measurement: Questionnaire including abdominal pain, frequency of defecation, mobility and endoscopy findings.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMashhad University of Medical Sciences

Mashhad University of Medical Sciences

fatemehamaanii@gmail.com+98 51 3871 3801

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026